RavasioR., AntonelliS., MaiorinoA., CostanzoA. and LosiS. (2019) “Cost per responder for ixekizumab and other biologic drugs approved for the treatment of moderate-to-severe plaque psoriasis in Italy”, Global & Regional Health Technology Assessment, 6(1). doi: 10.33393/grhta.2019.468.